May 22, 2015 / 1:23 PM / in 2 years

BUZZ-U.S. STOCKS ON THE MOVE-Viggle, eLong, Aeropostale, Otonomy

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, link.reuters.com/mex49s; for the Morning News Call newsletter, link.reuters.com/nex49s) U.S. stock futures reverse course to trade lower on Friday after data showed consumer prices moderated in April but core inflation rose, suggesting the Federal Reserve would remain on track to raise interest rates later this year. Dow Jones industrial average futures were down 0.12 percent at 18,237, S&P 500 futures were down 0.18 percent at 2,124.25 and Nasdaq 100 futures were down 0.06 percent at 4,526.25.

** EXPEDIA INC, Thursday close $105.89, +3.22 pct premarket

** ELONG INC, Thursday close $20.65, +34.62 pct premarket

** CTRIP.COM INTERNATIONAL LTD, Thursday close $71.99, +6.96 pct premarket

Expedia said it sold its entire stake in Chinese online travel company eLong to rival Ctrip.com and others for about $671 million.

** VIGGLE INC, Thursday close $3.09, -15.86 pct premarket

The web-based entertainment and marketing services provider announces a public offering of common shares. The size of the offering was not disclosed.

** OTONOMY INC, Thursday close $31.05, -19.68 pct premarket

The company said its experimental drug did not meet the main goal of reducing the incidence of vertigo in a mid-stage trial in patients suffering from Ménière’s disease.

** AEROPOSTALE INC, Thursday close $2.59, -15.06 pct premarket

The teen apparel retailer sees bigger current-quarter loss than average analyst estimate, citing higher store closure costs, supply delays due to disruptions at West Coast ports. The company expects second quarter gross margins to fall in low-to-mid-single digit percentage.

** NEOSTEM INC, Thursday close $2.95, +5.42 pct premarket

The cancer drug developer receives a $17.7 million grant from the California Institute for Regenerative Medicine to develop its treatment for a severe form of skin cancer. The drug, NBS20, is being tested in a late-stage study.

** FOOTLOCKER INC, Thursday close $64, +3.33 pct premarket

The footwear retailer’s profit and sales top estimates for the seventh quarter in a row. Unwarranted fears of a slowdown in sneaker sales provide an opportunity to own FL shares at a discount, Deutsche Bank says.

** CAMPBELL SOUP CO, Thursday close $46.93, +1.79 pct premarket

The packaged foods maker reported a better-than-expected quarterly profit, helped by lower promotions, higher selling prices and cost cuts.

** AMGEN INC, Thursday close $163.84, -0.02 pct premarket

Amgen’s closely watched new cholesterol drug, Repatha, has been recommended for approval in Europe, putting the U.S. drugmaker ahead in a race with rival Sanofi SA.

** HEWLETT-PACKARD CO, Thursday close $33.83, +0.74 pct premarket

HP will sell a controlling 51 percent stake in its China-based data-networking business to China’s Tsinghua Unigroup for at least $2.3 billion, forming a partnership designed to create a Chinese technology powerhouse.

** CHARTER COMMUNICATIONS INC, Thursday close $178.65

** TIME WARNER CABLE INC, Thursday close $165.52, +2.82 pct premarket

Charter is in talks with Time Warner Cable about a bid that is likely to be well above the $170 per share expected by some analysts, the Wall Street Journal reported, citing people familiar with the matter.

** WAL-MART STORES INC, Thursday close $76.11, -0.12 pct premarket

The world’s largest retailer said it had decided to bring in-house some of the product sourcing that has been handled by Direct Sourcing Group (DSG), a unit of Hong Kong’s Li & Fung Ltd .

** GAP INC, Thursday close $38.56, -0.80 pct premarket

The apparel retailer reported an 8 percent fall in quarterly profit, hurt by a stronger dollar, supply delays in the United States and lower demand for its namesake brand.

** FORD MOTOR CO, Thursday close $15.51, -0.32 pct premarket

** FIAT CHRYSLER AUTOMOBILES NV, Thursday close $15.87, -0.13 pct premarket

Production resumed at the Turkish operations of Ford and Fiat Chrysler on Friday after a labour dispute disrupted output for about a week and embarrassed the government ahead of a parliamentary election.

** GENERAL MOTORS CO, Thursday close $35.58, -0.59 pct premarket

U.S. regulators will oversee General Motors Co’s decision-making about potential vehicle safety issues for an additional year, the National Highway Traffic Safety Administration said on Thursday.

** REYNOLDS AMERICAN INC, Thursday close $75.49, +0.11 pct premarket

** LORILLARD INC, Thursday close $72, -0.14 pct premarket

Camel cigarette brand owner Reynolds American’s planned acquisition of smaller rival Lorillard is expected to receive U.S. antitrust clearance as soon as next week, the Wall Street Journal said.

** BLACKBERRY LTD, Thursday close $10.27, +2.04 pct premarket

The Canadian smartphone maker said it plans to buy back 12 million shares.

** ENDO INTERNATIONAL PLC, Thursday close $85

Specialty drugmaker Endo has agreed a $9.275 billion loan package backing its $8.05 billion acquisition of privately owned Par Pharmaceuticals, the borrower announced in an SEC filing on Thursday.

** HSBC HOLDINGS PLC, Thursday close $47.96, +0.60 pct premarket

HSBC is exploring the sale of its Brazilian unit after interest in the business stepped up and Santander’s Brazilian arm said it would consider a purchase.

** WESTPAC BANKING CORP, Thursday close $25.75, +0.04 pct premarket

- A recent entrant in Asia’s commodities markets, Australia’s Westpac is ramping up to take advantage of a commodities “supercycle” that it says has at least another 30 years to run.

** LOCKHEED MARTIN CORP, Thursday close $193.11

** BOEING CO, Thursday close $147.35, -0.38 pct premarket

United Launch Alliance, a 50-50 joint venture of Lockheed Martin and Boeing, on Thursday said it would go out of business unless it won commercial and civil satellite launch orders to offset an expected slump in U.S. military and spy launches.

** NEOPHOTONICS CORP, Thursday close $7.25, +2.07 pct premarket

The chipmaker announces pricing its 6-million share public follow-on offering at $7.25. Top holder Oak Investment Partners had indicated interest in buying up to $2 million of offering shares, according to the most recent filing.

** MERCK & CO INC, Thursday close $60.1, +0.00 pct premarket

European regulators have recommended approval of Merck’s immune system-boosting cancer drug Keytruda, following a similar green light last month for Bristol-Myers Squibb Co’s rival product Opdivo. (Compiled by Kshitiz Goliya in Bengaluru; Edited by Maju Samuel)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below